GLP1R and chronic kidney disease: Incident HF was observed in 7.6% of patients over three years, particularly among older adults, those with chronic kidney disease, or with limited access to guideline-recommended therapies such as sodium–glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [4].